TABLE 5.
Diseases and disorders associated with variations in endostatin levels
| Disease/Disorder | Endostatin Levels | Endostatin used for Treatment |
Endostatin as a Potential Prognostic Marker |
References | ||
|---|---|---|---|---|---|---|
| Percentage Change from Normal Levels |
Tissue or body fluid where endostatin has been measured |
Clinical Trial |
Animal Model |
|||
| Cancer | ||||||
| Hepatocellular Carcinoma | ≥ +169% | Liver Tissue | - | X | X | Hu et al. [197] Musso et al. [198, 199] |
| Bladder Cancer | ≥ +42% | Serum | - | X | X | Cheng et al. [200] Pan et al. [201] Du et al. [202] Szarvas et al. [203] |
| Cervical Cancer | ≥ +13% | Serum | X, Phase I | X | X | Landt et al. [204] Ke et al. [205] Jia et al. [206] |
| Colorectal Cancer | ≥ + 10% | Serum | X, Phase II | - | X | Xu et al. [207] Kantola et al. [208] Lee et al. [209] Chen et al. [210] ClinicalTrials.gov NCT01529164 |
| Nasopharyngeal Carcinoma | ≥ +23% | Serum | X, Phase III | - | X | Mo et al. [211] Ye et al. [212] Xu et al. [213] ClinicalTrials.gov NCT01915134 |
| Vascular Disease | ||||||
| Pulmonary Arterial Hypertension | ≥ +76% | Serum | - | - | X | Damico et al. [214] |
| Coronary Artery Disease with Diabetes Mellitus | ≥ +68% | Myocardial Tissue | - | - | - | Sodha et al. [185] Felbor et al. [190] Goldberg et al. [186] Helfant et al. [187] Hansen [188] Habib et al. [189] |
| Intermittent Claudication in Peripheral Vascular Disease | ≥ +22% | Serum | - | - | X | Golledge et al. [215] |
| Chronic Kidney Disease | ≥ +76% | Serum | - | - | X | Maeshima et al. [43] Lerman et al. [193] Stoessel et al. [194] O’Riord an et al. [195] Chen et al. [196] |
| Neurological Disease | ||||||
| Alzheimer’s Disease | ≥ +257% | Cerebrospinal Fluid and Brain Tissuea | - | - | X | Deininger et al. [128] Salza et al. [216] |
| Traumatic Brain Injury | ≥ +36% | Cerebrospinal Fluid | - | - | X | Chen et al. [217] Mueller et al. [218] |
| Other | ||||||
| Bronchopulmonary Dysplasia | ≥ +13% | Cord Plasma | - | - | X | Mohamed et al. [219] Janer et al. [220] |
| Corneal Graft Rejection | ≤−46% | Cornea | - | X | X | Tan et al. [221] |
| Rheumatoid Arthritis | No change | Joint Fluid | - | X | - | Huang et al. [222] Nagashima et al. [223] |
| Retinopathies | ≤−32% | Vitreous Fluid | - | X | X | Bai et al. [145] Funatsu et al. [224] |
| Malignant Pleural Effusion | ≥ +24% | Serum and Pleural Fluid | - | X | X | Ma et al. [177] Zhang et al. [225] Zhou et al. [226] |